Patel A, Gulhati P. Molecular landscape and therapeutic strategies against colorectal cancer. Cancers. 2024;16:1551. https://doi.org/10.3390/cancers16081551.
Google Scholar
Jia W, Shen X, Guo Z, Cheng X, Zhao R. The future of cancer vaccines against colorectal cancer. Expert Opin Biol Ther. 2024;1–16. https://doi.org/10.1080/14712598.2024.2341744.
Sharma S, Singh N, Turk AA, Wan I, Guttikonda A, Dong JL, et al. Molecular insights into clinical trials for immune checkpoint inhibitors in colorectal cancer: unravelling challenges and future directions. World J Gastroenterol. 2024;30:1815–35. https://doi.org/10.3748/wjg.v30.i13.1815.
Google Scholar
Marques A, Cavaco P, Torre C, Sepodes B, Rocha J. Tumor mutational burden in colorectal cancer: Implications for treatment. Crit Rev Oncol Hematol. 2024;197:104342. https://doi.org/10.1016/j.critrevonc.2024.104342.
Google Scholar
Lynch KT, Squeo GC, Kane WJ, Meneveau MO, Petroni G, Olson WC, et al. A pilot trial of vaccination with Carcinoembryonic antigen and Her2/neu peptides in advanced colorectal cancer. Int J Cancer. 2022;150:164–73. https://doi.org/10.1002/ijc.33793.
Google Scholar
Kim S, Kim BJ, Kim I, Kim JH, Kim HK, Ryu H, et al. A phase II study of chemotherapy in combination with telomerase peptide vaccine (GV1001) as second-line treatment in patients with metastatic colorectal cancer. J Cancer. 2022;13:1363–9. https://doi.org/10.7150/jca.70385.
Google Scholar
Schoen RE, Boardman LA, Cruz-Correa M, Bansal A, Kastenberg D, Hur C, et al. Randomized, double-blind, placebo-controlled trial of MUC1 peptide vaccine for prevention of recurrent colorectal adenoma. Clin Cancer Res. 2023;29:1678–88. https://doi.org/10.1158/1078-0432.CCR-22-3168.
Google Scholar
Shi R, Zhou X, Pang L, Wang M, Li Y, Chen C, et al. Peptide vaccine from cancer-testis antigen ODF2 can potentiate the cytotoxic T lymphocyte infiltration through IL-15 in non-MSI-H colorectal cancer. Cancer Immunol Immunother. 2023;72:985–1001. https://doi.org/10.1007/s00262-022-03307-0.
Google Scholar
Ahcene Djaballah S, Daniel F, Milani A, Ricagno G, Lonardi S. HER2 in colorectal cancer: the long and winding road from negative predictive factor to positive actionable target. Am Soc Clin Oncol Educ Book. 2022. https://doi.org/10.1200/EDBK_351354.
Kankanala VL, Mukkamalla SKR. Carcinoembryonic antigen. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024. https://www.ncbi.nlm.nih.gov/books/NBK578172/
Kasprzak A, Siodła E, Andrzejewska M, Szmeja J, Seraszek-Jaros A, Cofta S, et al. Differential expression of mucin 1 and mucin 2 in colorectal cancer. World J Gastroenterol. 2018;24:4164–77. https://doi.org/10.3748/wjg.v24.i36.4164].
Tarnowski M, Czerewaty M, Deskur A, Safranow K, Marlicz W, Urasińska E, et al. Expression of cancer testis antigens in colorectal cancer: new prognostic and therapeutic implications. Dis Markers. 2016;2016:1987505. https://doi.org/10.1155/2016/1987505.
Google Scholar
Park SC, Wiest MJ, Yan V, Wong PT, Schotsaert M. Induction of protective immune responses at respiratory mucosal sites. Hum Vaccin Immunother. 2024;20:2368288. https://doi.org/10.1080/21645515.2024.2368288.
Google Scholar
Feng F, Wen Z, Chen J, Yuan Y, Wang C, Sun C. Strategies to develop a mucosa-targeting vaccine against emerging infectious diseases. Viruses. 2022;14:520. https://doi.org/10.3390/v14030520.
Google Scholar
Li M, Wang Y, Sun Y, Cui H, Zhu SJ, Qiu HJ. Mucosal vaccines: strategies and challenges. Immunol Lett. 2020;217:116–25. https://doi.org/10.1016/j.imlet.2019.10.013.
Google Scholar
Kim KM, Ahn AR, Park HS, Jang KY, Moon WS, Kang MJ, et al. Clinical significance of p53 protein expression and TP53 variation status in colorectal cancer. BMC Cancer. 2022;22:940. https://doi.org/10.1186/s12885-022-10039-y.
Google Scholar
Liebl MC, Hofmann TG. The role of p53 signaling in colorectal cancer. Cancers. 2021;13:2125. https://doi.org/10.3390/cancers13092125.
Google Scholar
Wong PT, Wang SH, Ciotti S, Makidon PE, Smith DM, Fan Y, et al. Formulation and characterization of nanoemulsion intranasal adjuvants: effects of surfactant composition on mucoadhesion and immunogenicity. Mol Pharm. 2014;11:531–44.
Google Scholar
Tang J, Feng Y, Kuick R, Green M, Green M, Sakamoto N, et al. Trp53 null and R270H mutant alleles have comparable effects in regulating invasion, metastasis, and gene expression in mouse colon tumorigenesis. Lab Invest. 2019;99:1454–69. https://doi.org/10.1038/s41374-019-0269-y.
Google Scholar
Kim JK, Wu C, Del Latto M, Gao Y, Choi SH, Kierstead M, et al. An immunocompetent rectal cancer model to study radiation therapy. Cell Rep Methods. 2022;2:100353. https://doi.org/10.1016/j.crmeth.2022.100353.
Google Scholar
Arnesen H, Müller MHB, Aleksandersen M, Østby GC, Carlsen H, Paulsen JE, et al. Induction of colorectal carcinogenesis in the C57BL/6J and A/J mouse strains with a reduced DSS dose in the AOM/DSS model. Lab Anim Res. 2021;37:19. https://doi.org/10.1186/s42826-021-00096-y.
Google Scholar
Derwinger K, Kodeda K, Bexe-Lindskog E, Taflin H. Tumour differentiation grade is associated with TNM staging and the risk of node metastasis in colorectal cancer. Acta Oncol. 2010;49:57–62. https://doi.org/10.3109/02841860903334411.
Google Scholar
Luk IY, Mooi JK, Mouradov D, Tan T, Scott CM, Chionh F, et al. Model systems and unique biological features of high and low-grade colorectal cancer (CRC) revealed by xenografting 84 human CRC cell lines. Commun Biol. 2025;8:875. https://doi.org/10.1038/s42003-025-08251-0.
Google Scholar
Wang SH, Cao Z, Farazuddin M, Chen J, Janczak KW, Tang S, et al. A novel intranasal peptide vaccine inhibits non-small cell lung cancer with KRAS mutation. Cancer Gene Ther. 2024;31:464–71. https://doi.org/10.1038/s41417-023-00717-9.
Google Scholar
Tian Y, Li M, Yu C, Zhang R, Zhang X, Huang R, et al. The novel complex combination of alum, CpG ODN and HH2 as adjuvant in cancer vaccine effectively suppresses tumor growth in vivo. Oncotarget. 2017;8:45951–64. https://doi.org/10.18632/oncotarget.17504.
Google Scholar
deLahunta D, Nalamati S. Management of surgically accessible lymph nodes beyond normal resection planes. Clin Colon Rectal Surg. 2023;37:71–79. https://doi.org/10.1055/s-0043-1761474.
Google Scholar
Ghirardello M, Guerreiro A, Bretón C, Compañón I, Zabalza J, Mangini V, et al. Balancing antigen loading on gold nanoparticles: implications for future cancer vaccine strategies. Chemistry. 2025:e202501286. https://doi.org/10.1002/chem.202501286.
Nishida S, Morimoto S, Oji Y, Morita S, Shirakata T, Enomoto T, et al. Cellular and humoral immune responses induced by an HLA class I-restricted peptide cancer vaccine targeting WT1 are associated with favorable clinical outcomes in advanced ovarian cancer. J Immunother. 2022;45:56–66. https://doi.org/10.1097/CJI.0000000000000405.
Google Scholar
Markowski AR, Markowska AJ, Ustymowicz W, Pryczynicz A, Guzińska-Ustymowicz K. Simultaneous analysis of tumor-infiltrating immune cells density, tumor budding status, and presence of lymphoid follicles in CRC tissue. Sci Rep. 2022;12:21732. https://doi.org/10.1038/s41598-022-26225-8.
Google Scholar
Guo L, Wang C, Qiu X, Pu X, Chang P. Colorectal cancer immune infiltrates: significance in patient prognosis and immunotherapeutic efficacy. Front Immunol. 2020;11:1052. https://doi.org/10.3389/fimmu.2020.01052.
Google Scholar
Chiappori AA, Williams CC, Gray JE, Tanvetyanon T, Haura EB, Creelan BC, et al. Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer. Cancer Immunol Immunother. 2019;68:517–27. https://doi.org/10.1007/s00262-018-2287-9.
Google Scholar
Quandt J, Schlude C, Bartoschek M, Will R, Cid-Arregui A, Schölch S, et al. Long-peptide vaccination with driver gene mutations in p53 and Kras induces cancer mutation-specific effector as well as regulatory T cell responses. Oncoimmunology. 2018;7:e1500671. https://doi.org/10.1080/2162402X.2018.1500671.
Google Scholar
Zeestraten EC, Speetjens FM, Welters MJ, Saadatmand S, Stynenbosch LF, Jongen R, et al. Addition of interferon-α to the p53-SLP® vaccine results in increased production of interferon-γ in vaccinated colorectal cancer patients: a phase I/II clinical trial. Int J Cancer. 2013;132:1581–91. https://doi.org/10.1002/ijc.27819.
Google Scholar
Speetjens FM, Kuppen PJ, Welters MJ, Essahsah F, Voet van den Brink AM, Lantrua MG, et al. Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer. Clin Cancer Res. 2009;15:1086–95. https://doi.org/10.1158/1078-0432.CCR-08-2227.
Google Scholar
van der Burg SH, Menon AG, Redeker A, Bonnet MC, Drijfhout JW, Tollenaar RA, et al. Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine. Clin Cancer Res. 2002;8:1019–27.
Google Scholar
Shang Q, Yu X, Sun Q, Li H, Sun C, Liu L. Polysaccharides regulate Th1/Th2 balance: A new strategy for tumor immunotherapy. Biomed Pharmacother. 2024;170:115976. https://doi.org/10.1016/j.biopha.2023.115976.
Google Scholar
Zheng Z, Wieder T, Mauerer B, Schäfer L, Kesselring R, Braumüller H. T cells in colorectal cancer: unravelling the function of different T cell subsets in the tumor microenvironment. Int J Mol Sci. 2023;24:11673. https://doi.org/10.3390/ijms241411673.
Google Scholar
Qu Y, Yang H, Li S, Li L, Li Y, Wang D. The involvement of Th1 cell differentiation in the anti-tumor effect of purified polysaccharide from Sanghuangporus vaninii in colorectal cancer via multi-omics analysis. Int J Biol Macromol. 2023;237:123927. https://doi.org/10.1016/j.ijbiomac.2023.123927.
Google Scholar
Luo X, Song Z, Zeng X, Ye Y, Zheng H, Cai D, et al. A promising self-nanoemulsifying adjuvant with plant-derived saponin D boosts immune response and exerts an anti-tumor effect. Front Immunol. 2023;14:1154836. https://doi.org/10.3389/fimmu.2023.1154836.
Google Scholar
Guo L, Overholser J, Darby H, Ede NJ, Kaumaya PTP. A newly discovered PD-L1 B-cell epitope peptide vaccine (PDL1-Vaxx) exhibits potent immune responses and effective anti-tumor immunity in multiple syngeneic mice models and (synergizes) in combination with a dual HER-2 B-cell vaccine (B-Vaxx). Oncoimmunology. 2022;11:2127691. https://doi.org/10.1080/2162402X.2022.2127691.
Google Scholar
Rodriguez C, Araujo Furlan CL, Tosello Boari J, Bossio SN, Boccardo S, Fozzatti L, et al. Interleukin-17 signaling influences CD8+ T cell immunity and tumor progression according to the IL-17 receptor subunit expression pattern in cancer cells. Oncoimmunology. 2023;12:2261326. https://doi.org/10.1080/2162402X.2023.2261326.
Google Scholar
Kuen DS, Kim BS, Chung Y. IL-17-producing cells in tumor immunity: friends or foes?. Immune Netw. 2020;20:e6. https://doi.org/10.4110/in.2020.20.e6.
Google Scholar
Hassin O, Oren M. Drugging p53 in cancer: one protein, many targets. Nat Rev Drug Discov. 2023;22:127–44. https://doi.org/10.1038/s41573-022-00571-8.
Google Scholar
Peng Y, Bai J, Li W, Su Z, Cheng X. Advancements in p53-based anti-tumor gene therapy research. Molecules. 2024;29:5315. https://doi.org/10.3390/molecules29225315.
Google Scholar
Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol. 2005;23:515–48.
Google Scholar
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–64.
Google Scholar
Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:568–71. https://doi.org/10.1038/nature13954.
Google Scholar
Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2023;41:715–23. https://doi.org/10.1200/JCO.22.02270. Feb 1PMID: 36706735.
Google Scholar
Li J, Lv M, Huang Q, Hu R, Zhong X, Sun X, et al. FAT4 expression in peripheral blood mononuclear cells is associated with prognosis and immune cell infiltration in hepatocellular carcinoma. Sci Rep. 2023;13:15735. https://doi.org/10.1038/s41598-023-42560-w.
Google Scholar
Bazzi ZA, Sneddon S, Zhang PGY, Tai IT. Characterization of the immune cell landscape in CRC: clinical implications of tumour-infiltrating leukocytes in early- and late-stage CRC. Front Immunol. 2023;13:978862. https://doi.org/10.3389/fimmu.2022.978862.
Google Scholar
Qi Z, Zhibo Z, Jing Z, Zhanbo Q, Shugao H, Weili J, et al. Prediction model of poorly differentiated colorectal cancer (CRC) based on gut bacteria. BMC Microbiol. 2022;22:312. https://doi.org/10.1186/s12866-022-02712-w.
Google Scholar
Wang S, Fan X, Zhu J, Xu D, Li R, Chen R, et al. The differentiation of colorectal cancer is closely relevant to m6A modification. Biochem Biophys Res Commun. 2021;546:65–73. https://doi.org/10.1016/j.bbrc.2021.02.001.
Google Scholar
